137 articles about LEO Pharma
LEO Pharma and Research Project BIOMAP: Towards Personalised Medicine for Inflammatory Skin Diseases
The large-scale IMI project will investigate the causes and mechanisms of Atopic Dermatitis and Psoriasis
LEO Pharma and Elektrofi Expand Partnership to Co-Develop New Antibodies with the Aim of Achieving Improvements in Drug Delivery within Dermatology
LEO Pharma A/S and Elektrofi announced an expansion of the two companies’ partnership agreement to further include antibodies from LEO Pharma’s pipeline with the aim of achieving improvements in drug delivery within dermatology.
LEO Pharma Showcases Data in Four Disease Areas at 2019 American Academy of Dermatology Annual Meeting in Washington, D.C.
LEO Pharma A/S announced that 13 data abstracts, including seven oral presentations across atopic dermatitis, chronic hand eczema, psoriasis and actinic keratosis will be presented during the 2019 American Academy of Dermatology Annual Meeting in Washington, D.C.
Olivier Bohuon Elected New Chairman of LEO Pharma’s Board of Directors
LEO Pharma announced changes to its Board of Directors.
LEO Pharma Annual Results 2018: A Year in Line with Expectations
LEO Pharma A/S announced its annual results for 2018 and outlined expectations for 2019.
LEO Pharma Scientists Win Innovator of the Year 2019 Award from Innovation Fund Denmark
LEO Pharma, a global leader in medical dermatology, today announced that two of the company’s scientists have been awarded Innovation Fund Denmark’s Innovator of the Year Award 2019.
BioSpace Movers and Shakers: Feb. 1
2/1/2019As January ends, biotech and pharma companies tap new leaders to help drive strategic visions. New hires at Histogen, Indalo, Novartis Oncology, Calico, and more.
LEO Pharma Further Boosts Focus on Translational Medicine with the Appointment of Thomas Hultsch, M.D., Ph.D., as Head of Translational Medicine
LEO Pharma announced that Thomas Hultsch has been appointed as Head of Translational Medicine as of 28 January, 2019.
BioSpace Movers and Shakers: Jan. 11
1/11/2019Biopharma companies strengthen the leadership teams during the annual J.P. Morgan Healthcare Conference.
LEO Pharma Strengthens Focus on Translational Medicine with the Appointment of Adam B. Raff, M.D., Ph.D., as Director and Medical Advisor
LEO Pharma announced that Adam B. Raff has been appointed as Director and Medical Advisor in Translational Medicine as of January 28, 2019
LEO Pharma initiates phase 2b clinical studies of topical delgocitinib cream in adults for the treatment of both atopic dermatitis and chronic hand eczema
LEO Pharma A/S announces today that it has enrolled the first patients in two new phase 2b clinical studies to investigate delgocitinib, a novel topical pan-Janus kinase inhibitor (JAKi), as a monotherapy for adults with mild-to-severe atopic dermatitis (AD) as well as mild-to-severe chronic hand eczema (CHE).
PellePharm’s Phase III Skin Disease Trial Is Back on Track Following Agreement With LEO Pharma
11/20/2018Denmark-based LEO Pharma and California rare disease drugmaker PellePharm entered into a strategic collaboration worth $760 million to address unmet needs in multiple orphan skin diseases, such as Gorlin Syndrome and High-Frequency Basal Cell Carcinomas (BCCs), two rare forms of skin cancer.
Enstilar is now covered by the Non-Insured Health Benefits Program for Adults with Psoriasis Vulgaris
LEO Pharma Canada has announced that as of October 15th, 2018, Enstilar® has been added as a benefit through the Non-Insured Health Benefits (NIHB) Program for eligible First Nations and Inuit people across Canada.
LEO Science & Tech Hub Partners with Wearifi and Northwestern University to Develop Wearable Device for Dermatology Research
Wearifi designs and develops the world’s smallest, battery-free wearable device.
Zymeworks and LEO Pharma Enter into Bispecific Antibody Licensing and Research Collaboration.
Zymeworks Inc. and LEO Pharma A/S have entered into a licensing and research collaboration to discover and develop bispecific antibodies.
World Psoriasis Day 2018: LEO Pharma Urges People to Connect with What’s under the Skin of Psoriasis to See the Seriousness of the Condition
New global campaign and report highlights the impact the condition can have on the wider wellbeing of the 125 million people living with the disease
MorphoSys and LEO Pharma Expand Strategic Alliance to Develop Peptide-derived Therapeutics
LEO Pharma A/S and MorphoSys AG today announced an expansion of their existing strategic alliance to include peptide-derived therapeutics.
EBD Group: Global life sciences to convene in Copenhagen for Europe's largest annual biopharma partnering conference
The 24th annual BIO-EUROPE (R) 2018 Global Life Science Partnership event will be held November 5-7, 2018, in Copenhagen, Denmark.
Almirall, headquartered in Barcelona, Spain, announced it is buying five dermatology products from Allergan. Those include Aczone (dapsone), Tazorac (tazarotene), Azelex (azelaic acid), Cordran Tape (fludroxycortide) and Seysara (sarecycline).
UTILITY therapeutics signs license agreement with LEO Pharma A/S for US rights to mecillinam and pivmecillinam
UTILITY therapeutics Ltd (“UTILITY” or “the Company”), a pharmaceutical company focused on developing and commercialising antibiotics in the US, today announces the signature of an exclusive license agreement for the antibiotics mecillinam and pivmecillinam with LEO Pharma A/S.